10 Best ATAI Life Sciences Alternatives & Competitors (2026)

COMPASS Pathways develops psilocybin-based therapies for treatment-resistant depression with a focus on large Phase 3 trials and therapist-supported sessions. Its longer-duration psychedelic experience contrasts with Gilgamesh's short-acting 5-HT2AR agonist designed for a 2-hour window and potential scalability advantages post-AbbVie acquisition.

MindMed advances MM-120, a lysergide d-tartrate for anxiety disorders, and other psychedelic-inspired candidates. Its focus on regulated psychedelic sessions differs from Gilgamesh's emphasis on non-hallucinogenic neuroplastogens and oral NMDAR antagonists suitable for at-home use.

Cybin develops deuterated tryptamine analogs for depression and anxiety with improved pharmacokinetics. Its shorter-acting candidates share some mechanistic overlap with Gilgamesh's Bretisilocin but lack the same level of big-pharma acquisition validation to date.

Delix specializes in non-hallucinogenic psychoplastogens targeting structural brain plasticity. Its approach closely mirrors Gilgamesh's AbbVie-partnered neuroplastogen program, though Delix remains independent without equivalent late-stage partnership announcements.

Seelos focuses on CNS candidates including SLS-002, an intranasal racemic ketamine for depression and suicidality. Its acute-use formulation differs from Gilgamesh's oral daily-potential NMDAR antagonist aimed at broader outpatient access.

Beckley Psytech develops synthetic 5-MeO-DMT and other short-acting psychedelics for depression. Its emphasis on rapid-onset, shorter-duration compounds parallels Gilgamesh's 5-HT2AR strategy but without the same disclosed big-pharma exit.

Small Pharma advances SPL026, a DMT-based short-acting psychedelic for depression. Its pharmacokinetic profile resembles Gilgamesh's Bretisilocin yet remains pre-partnership compared to the AbbVie-validated asset.

Lundbeck develops established psychiatric medications and has explored novel mechanisms for depression. As a large pharma, it offers approved products and global reach unlike Gilgamesh's early-clinical NCE pipeline focused on plasticity mechanisms.

J&J markets Spravato (esketamine) nasal spray for depression. Its approved, monitored administration model contrasts with Gilgamesh's pipeline goal of low-dissociation oral agents potentially suitable for at-home psychiatric treatment.